(SNN) Smith & Nephew SNATS - Overview

Exchange: NYSE • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: US83175M2052

Stock:

Total Rating 62

Risk 92

Buy Signal -0.65

Medical Devices +5.3
Health Care Equipment +4.0

Market Cap: 15,336m
Avg Trading Vol: 27.1M USD

ATR: 1.89%
Peers RS (IBD): 70.43

Risk 5d forecast
Volatility	26.2%
Relative Tail Risk	-10.6%

Reward TTM
Sharpe Ratio	1.18
Alpha	35.23

Character TTM
Beta	0.543
Beta Downside	0.257

Drawdowns 3y
Max DD	33.29%
CAGR/Max DD	0.33

EPS (Earnings per Share)

EPS CAGR: -73.48%
EPS Trend: 4.5%

Last SUE: 0.00
Qual. Beats: 0

Revenue

Rev. CAGR: 24.86%
Rev. Trend: 39.8%

Qual. Beats: 0

Description: SNN Smith & Nephew SNATS

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. It operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Piotroski VR‑10 (Strict, 0-10) 8.0

Net Income: 814.6m TTM > 0 and > 6% of Revenue
FCF/TA: 0.08 > 0.02 and ΔFCF/TA 5.42 > 1.0
NWC/Revenue: 30.20% < 20% (prev 21.13%; Δ 9.06% < -1%)
CFO/TA 0.14 > 3% & CFO 1.51b > Net Income 814.6m
Net Debt (2.78b) to EBITDA (2.22b): 1.25 < 3
Current Ratio: 3.00 > 1.5 & < 3
Outstanding Shares: last quarter (439.9m) vs 12m ago -49.60% < -2%
Gross Margin: 69.95% > 18% (prev 0.70%; Δ 6925 % > 0.5%)
Asset Turnover: 98.80% > 50% (prev 83.34%; Δ 15.46% > 0%)
Interest Coverage Ratio: 4.98 > 6 (EBITDA TTM 2.22b / Interest Expense TTM 254.8m)

Altman Z'' 5.29

A: 0.29 (Total Current Assets 4.62b - Total Current Liabilities 1.54b) / Total Assets 10.68b
B: 0.48 (Retained Earnings 5.12b / Total Assets 10.68b)
C: 0.12 (EBIT TTM 1.27b / Avg Total Assets 10.33b)
D: 0.96 (Book Value of Equity 4.96b / Total Liabilities 5.15b)
Altman-Z'' Score: 5.29 = AAA

Beneish M -2.83

DSRI: 1.14 (Receivables 1.48b/1.06b, Revenue 10.21b/8.32b)
GMI: 1.00 (GM 69.95% / 70.14%)
AQI: 0.96 (AQ_t 0.43 / AQ_t-1 0.45)
SGI: 1.23 (Revenue 10.21b / 8.32b)
TATA: -0.06 (NI 814.6m - CFO 1.51b) / TA 10.68b)
Beneish M-Score: -2.83 (Cap -4..+1) = A

What is the price of SNN shares?

As of February 24, 2026, the stock is trading at USD 36.19 with a total of 336,937 shares traded.
Over the past week, the price has changed by +1.32%, over one month by +8.65%, over three months by +10.07% and over the past year by +41.15%.

Is SNN a buy, sell or hold?

Smith & Nephew SNATS has received a consensus analysts rating of 3.75. Therefor, it is recommend to hold SNN.

StrongBuy: 1
Buy: 1
Hold: 2
Sell: 0
StrongSell: 0

What are the forecasts/targets for the SNN price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	36.4	0.6%
Analysts Target Price	36.4	0.6%

SNN Fundamental Data Overview February 24, 2026

P/E Trailing = 32.2589
P/E Forward = 13.6054
P/S = 2.58
P/B = 2.802
P/EG = 0.896
Revenue TTM = 10.21b USD
EBIT TTM = 1.27b USD
EBITDA TTM = 2.22b USD
Long Term Debt = 3.15b USD (from longTermDebt, last quarter)
Short Term Debt = 156.9m USD (from shortTermDebt, last quarter)
Debt = 3.45b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.78b USD (from netDebt column, last quarter)
Enterprise Value = 18.11b USD (15.34b + Debt 3.45b - CCE 675.4m)
Interest Coverage Ratio = 4.98 (Ebit TTM 1.27b / Interest Expense TTM 254.8m)
EV/FCF = 20.16x (Enterprise Value 18.11b / FCF TTM 898.3m)
FCF Yield = 4.96% (FCF TTM 898.3m / Enterprise Value 18.11b)
FCF Margin = 8.80% (FCF TTM 898.3m / Revenue TTM 10.21b)
Net Margin = 7.98% (Net Income TTM 814.6m / Revenue TTM 10.21b)
Gross Margin = 69.95% ((Revenue TTM 10.21b - Cost of Revenue TTM 3.07b) / Revenue TTM)
Gross Margin QoQ = 70.62% (prev 69.46%)
Tobins Q-Ratio = 1.70 (Enterprise Value 18.11b / Total Assets 10.68b)
Interest Expense / Debt = 2.37% (Interest Expense 81.7m / Debt 3.45b)
Taxrate = 19.06% (69.6m / 365.3m)
NOPAT = 1.03b (EBIT 1.27b * (1 - 19.06%))
Current Ratio = 3.00 (Total Current Assets 4.62b / Total Current Liabilities 1.54b)
Debt / Equity = 0.62 (Debt 3.45b / totalStockholderEquity, last quarter 5.53b)
Debt / EBITDA = 1.25 (Net Debt 2.78b / EBITDA 2.22b)
Debt / FCF = 3.09 (Net Debt 2.78b / FCF TTM 898.3m)
Total Stockholder Equity = 5.30b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.88% (Net Income 814.6m / Total Assets 10.68b)
RoE = 15.37% (Net Income TTM 814.6m / Total Stockholder Equity 5.30b)
RoCE = 15.01% (EBIT 1.27b / Capital Employed (Equity 5.30b + L.T.Debt 3.15b))
RoIC = 11.92% (NOPAT 1.03b / Invested Capital 8.62b)
WACC = 6.81% (E(15.34b)/V(18.79b) * Re(7.91%) + D(3.45b)/V(18.79b) * Rd(2.37%) * (1-Tc(0.19)))
Discount Rate = 7.91% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -29.01%
[DCF Debug] Terminal Value 83.45% ; FCFF base≈658.4m ; Y1≈705.2m ; Y5≈856.6m
Fair Price DCF = 39.25 (EV 19.44b - Net Debt 2.78b = Equity 16.66b / Shares 424.5m; r=6.81% [WACC]; 5y FCF grow 7.97% → 2.90% )
EPS Correlation: 4.50 | EPS CAGR: -73.48% | SUE: 0.0 | # QB: 0
Revenue Correlation: 39.77 | Revenue CAGR: 24.86% | SUE: N/A | # QB: 0
EPS next Year (2026-12-31): EPS=1.81 | Chg30d=+0.009 | Revisions Net=+2 | Growth EPS=+12.3% | Growth Revenue=+5.6%

Additional Sources for SNN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle